Reducing incidence of cervical cancer: knowledge and attitudes of caregivers in Nigerian city to human papilloma virus vaccination

Adaobi I. Bisi-Onyemaechi 1*, Ugo N. Chikani 1 and Obinna Nduagubam 2

Abstract

Background: Despite the high prevalences of Human Papilloma Virus (HPV) infections and cervical cancer in Nigeria, utilization of the HPV vaccine as a highly effective preventive measure remains low. The aim of this study was to find out the awareness and attitudes of caregivers to HPV infections and the factors that determine acceptance of an HPV vaccine for their pre-adolescent girls.

Methods: This was a cross-sectional descriptive study of 508 caregivers of female children in Enugu Nigeria. A semi-structured questionnaire was used to collect information on knowledge of HPV, cervical cancer as well HPV vaccine and its acceptance for pre-adolescent female children. The data was analysed using descriptive statistics.

Results: Five hundred and eight (508) caregivers of female children were interviewed. Less than half, 221 (43.5%) of them knew about HPV, among these, 163 knew how HPV is transmitted. Only 12 (2.4%) of the caregivers know that an HPV infection is a major risk factor for cervical cancer. Among the 221 participants who knew the meaning of HPV, 132 (59.7%) were aware of an HPV vaccine. Only 26 (19.7%) of those aware of a vaccine agreed it can effectively prevent cervical cancer. Lack of awareness about the vaccine and accessibility were the major reasons given by parents on why the vaccine has not been received by their female children.

Conclusion: Despite high levels of education, awareness of HPV, HPV vaccine and the risks for cervical cancer remains low among caregivers in Enugu, south-east, Nigeria. Awareness and accessibility were the major determinants of HPV vaccine uptake among the caregivers. There is a need for massive and sustained awareness creation to increase HPV vaccination uptake in Nigeria.

Keywords: Awareness, Human papilloma virus, Cervical cancer, Vaccines, Nigeria

Background

Human Papilloma Virus (HPV) is the most common sexually transmitted virus and it is estimated that about 75% of sexually active women and men will acquire a genital HPV infection at some time [1]. HPV is known to affect adult and children alike and over 100 types of the HPV has been identified over the past few decades [2].

There has been an increasing interest in HPV because of their relationship with tumours particularly cervical. Epidemiological, molecular and clinical evidence has shown that cervical cancer is caused by HPV. About 13 genotypes are closely linked with cervical cancer especially genotypes 16 and 18 [3–11]. High risk Infections is usually persistent and should be the target of vaccination strategies [12].

Globally, cervical cancer is a major public health problem. Over 560,000 new cases and about 275,000 deaths are recorded each year, with more than 80% occurring in developing countries [13, 14]. It is the most common gynaecological cancer among women in sub-Saharan Africa [15]. It is estimated that 70,722 new cases of invasive cervical cancer occur annually in sub-Saharan Africa [16]. According to GLOBOCAN 2008, about 14,089 new cervical cancer cases are diagnosed annually in Nigeria.
Cervical cancer is the second most common cancer in Nigeria and second to breast cancer among its female population [17–21]. In 2007, it was reported that 36.59 million women aged more than 15 years in Nigeria are at risk of developing cervical cancer. There are 9922 cases diagnosed annually with 8030 deaths. HPV prevalence is 24.8%. Incidence of cervical cancer in Nigeria is 250/100,000 women [22]. One of the preventive measures is the vaccination of pre-adolescents against oncogenic HPV. The vaccines are approved for administration to persons aged 9–26 years [9, 23, 24]. The target is to commence the vaccine among young children before they become sexually active. The cervical cancer control plan in Nigeria recommends visual inspection with acetic acid (VIA) or with Lugol’s iodine, for screening, (secondary prevention strategy) of sexually-exposed women, and for primary prevention, HPV vaccination for girls aged 9 to 15 years. HPV vaccination has not been introduced in the vaccination schedule in Nigeria and is only available to people on personal arrangements. Programs are set up to vaccinate girls on adhoc, irregular and usually private basis.

A large number of European countries as well as United States, Australia and New Zealand have recommended including an HPV vaccine in the school vaccination program for young adolescent girls, often coupled with a catch-up program for older teenage girls [25, 26]. The vaccine has been found 70–100% effective in preventing cervical cancers [27–30]. The vaccines were licensed and introduced in Nigeria in 2009, uptake has ranged between 0 and 49% being utilized by only a few privileged population [30–32].

The knowledge of HPV infections and HPV vaccines, among the Nigeria population, are inadequate, and the cost of HPV vaccination per person is beyond what the average Nigerian can afford [33–36].

Awareness and knowledge of the infections and the vaccines would stimulate demand and uptake of the vaccines. Increasing demand may drive the introduction of the vaccine into the national immunization schedule thereby making the vaccine more affordable and accessible.

The aim of this study was to find out the knowledge and attitudes of parents to and the factors that determine the demand of HPV vaccine for their adolescent girls. This study was focused on the usefulness of HPV Vaccine as a preventive measure for the reduction of the incidence of cervical cancer hence the focus only on adolescent girls.

Methods
This was a cross-sectional descriptive study of 508 parents/caregivers of young children from primary schools in the three Local government councils of Enugu metropolis-Enugu-South, Enugu- North and Enugu-East. Fifteen primary schools were (five from each local council) were randomly selected for the study. The researchers attended the Parents- Teachers forum of these schools. During the meeting, the researchers introduced themselves and the purpose of their research. They were then granted permission to administer the questionnaire to consenting parents of female children. Every eligible caregiver of a female child less than 18 years was recruited into the study. The data was collected consecutively from school to school. Data was collected between the months of January and July 2017. Data collection tool was semi-structured questionnaire reviewed by a panel of experts for validity. The questionnaire was either self-administered or interviewer-administered for study participants who were not literate. Items on the questionnaire include; socio-demographic variables; knowledge of cervical cancer; knowledge of HPV infections and HPV vaccines, their attitudes towards the effectiveness of the vaccines and reason(s) for uptake or otherwise of these vaccines for their adolescent girls. The data was analysed using descriptive statistics.

Results
A total of 508 caregivers were interviewed out of which 476 (93.7%) were below the age of 50 years. 385 (75.8%) were females and 123 (24.2%) males. Out of the 508 caregivers, 218 (42.9%) had more than one female child. The mean age of the children of the respondents was 7.3 years (SD = 3.3) Three hundred and forty-seven (68.3%) had tertiary level of education while only 30 (5.9%) had no formal education. Three hundred and thirty (65%) caregivers were married (Table 1).

A total of 221 (43.5%) parents knew what HPV meant, among these, 163(74%) knew how it is transmitted (Tables 2 and 3).

Overall, only 21 (9.5%) of the parents who were aware of HPV knew the risk factors for genital HPV infections while a total of 66 (30%) of these knew that the risk of developing invasive cervical cancer is the major “sequale” following HPV infection (Tables 3 and 4).

Although 361(71%) of the respondents have heard about cancer of the cervix, 65% of them did not know what it means. Only 12 out of the 221(5.4%) participants that know about HPV are aware that it is risk factor for developing cervical cancer. These 12 were part of the 66 who identified that risk of developing cervical cancer as a sequale of genital HPV infections (Table 5).

Among the 221 participants who knew the meaning of HPV, 132 (59.7%) were aware of HPV vaccine. Furthermore, of the 132 participants who are aware of the HPV vaccine; only 26 (19.7%) agree that HPV vaccine can effectively prevent cervical cancer; 59(44.7%) didn’t think so while 47(35.6%) had no idea.

Among those aware of the vaccine, 72 (54.5%) do not know what ages the HPV vaccine should be administered and only 6(2.75%) of the parents had given HPV vaccine to their eligible female children.
The major reasons given by parents/caregivers for not giving HPV vaccine to their eligible children were that they were not aware of the vaccine (74.1%) and inability to access the vaccine among those aware of it (72.5%) (Table 6).

Discussion

It was observed that many the study participants had formal education. The finding that 68.3% of the respondents had tertiary level of education signifies a high literacy level. However, despite this, awareness of cancer of cervix amongst them was low. This finding is similar to other studies in Nigeria, among women with similar social characteristics (age and educational attainment) where only a small proportion of respondents knew about the disease despite high levels of literacy [11, 36].

| Table 1 | Socio-demographic information of study participants |
|---------|--------------------------------------------------|
| Age group | Frequency | Percent |
| < =25 | 116 | 22.8 |
| 26–30 | 86 | 16.9 |
| 31–35 | 94 | 18.5 |
| 36–40 | 87 | 17.1 |
| 41–45 | 62 | 12.2 |
| 46–50 | 31 | 6.1 |
| > 50 | 32 | 6.3 |
| Sex | | |
| Male | 123 | 24.2 |
| Female | 385 | 75.8 |
| No of female children | Frequency | Percent |
| 1 | 290 | 57.1 |
| 2 | 22 | 4.3 |
| 3 | 50 | 9.8 |
| 4 | 67 | 13.2 |
| > 4 | 79 | 15.6 |
| Level of education | | |
| None | 30 | 5.9 |
| Primary | 29 | 5.7 |
| Secondary | 102 | 20.1 |
| Tertiary | 347 | 68.3 |
| Marital Status | | |
| Single | 154 | 30.3 |
| Married | 330 | 65.0 |
| Divorced | 7 | 1.4 |
| Separated | 17 | 3.3 |

| Table 2 | Knowledge about HPV |
|---------|---------------------|
| What is HPV | Frequency | Percent |
| Don’t know | 200 | 39.4 |
| Human papilloma virus | 221 | 43.5 |
| It’s a very bad disease | 1 | 0.2 |
| It’s a virus and very deadly disease | 1 | 0.2 |
| Hepatitis vaccine | 44 | 8.7 |
| Human productivity virus | 25 | 4.9 |
| High power voltage | 1 | 0.2 |
| High productivity vaccine | 8 | 1.6 |
| Human power | 1 | 0.2 |
| A vaccine | 1 | 0.2 |
| Human positive virus | 2 | 0.4 |
| Hypertension | 2 | 0.4 |
| Human production value | 1 | 0.2 |

| Table 3 | Knowledge about the risk factors for HPV infection |
|---------|-----------------|
| What are the risk factors for HPV infection? | Frequency | Percent |
| Don’t know | 89 | 40.3 |
| Unprotected sex and multiple partners | 20 | 9.0 |
| Frequent cervical contact | 1 | 0.5 |
| Cancer and genital warts | 15 | 6.8 |
| Death | 22 | 10.0 |
| Promiscuity | 58 | 26.2 |
| Adolescence | 2 | 0.9 |
| Use of condom | 1 | 0.5 |
| Infection | 2 | 0.9 |
| In the womb | 1 | 0.5 |
| Early sex | 1 | 0.5 |
| Child birth | 1 | 0.5 |
| Stroke | 1 | 0.5 |
| Bleeding | 1 | 0.5 |
| Sickness | 2 | 0.9 |
| Vaginal discomfort | 4 | 1.9 |
| Total | 221 | 100.0 |

| Table 4 | Knowledge of the sequel of genital HPV infections |
|---------|-----------------|
| What is the hazard for HPV infection? | Frequency | Percent |
| Don’t know | 96 | 43.4 |
| Risk of having cervical cancer | 66 | 29.9 |
| Death | 51 | 23.1 |
| Multiple sex partner | 1 | 0.5 |
| Infection | 2 | 0.9 |
| Yellow fever in fetus | 1 | 0.5 |
| Injury in the cervix | 1 | 0.5 |
| Bleeding | 1 | 0.5 |
| Chemical radiation | 1 | 0.5 |
| Genital warts | 1 | 0.5 |
| Total | 221 | 100.0 |
However, in contrast, a similar study Ibadan that reported that awareness of cancer of cervix was up to 67% despite lower literacy level among the study participants [30, 35]. Another study in Lagos Nigeria reported an awareness level of up to 99% among nurses which is not unexpected as they were health workers with more access to health information [36].

Awareness about HPV infection was also low in this study; very few caregivers knew the risk factors for HPV infection as well as the relationship between HPV infection and cervical cancer. This may be because it is not part of routine health talks at ante-natal or immunization sessions. These are the major places where most mothers get health information in this environment with limited access to internet and electricity. Similar finding of low awareness about HPV were also found in Lagos and Malaysia where only less than half of the mothers with similar educational attainment were aware of HPV disease [34]. However, in Ibadan Nigeria, awareness of HPV disease was found to be high [30]. This low level of awareness among the educated implies that a lot of information, communication and education strategies have to be engaged to enlighten the public on a prevalent disease like cervical cancer. Health promotion strategies to educate the public about prevention of STIs of public health significance can be effective in preventing genital HPV infection and by extension cervical cancer [24].

Primary prevention of cervical cancer can be achieved through prevention and control of genital infection with oncogenic HPV types [24]. Oncogenic genital HPV infections can be prevented by vaccinating young female children with HPV vaccine. In Nigeria, mothers influence decision making particularly for their young female children; hence places with high concentration of mothers like antenatal classes, markets and parent-teachers forum meetings can be engaged to improve HPV awareness.

This study is similar to a number of other studies which have shown that awareness of the vaccine is also very low [11, 34, 35]. Also, more 90% of the respondents who were aware of the HPV vaccine cannot access it. This is worrisome because effective coverage of HPV vaccination requires both caregiver acceptance of the vaccines [5, 9] accessibility and affordability. Uptake rates cannot be improved when basic knowledge is lacking and vaccines inaccessible. This would result in underutilization of this preventive measure as was the case in this study.

As much as 45% of those aware of the vaccine do not agree that HPV vaccine can effectively prevent cervical cancer. Cost of the vaccine, concerns about the effectiveness and safety of the vaccine were reasons given by the caregivers for poor uptake of HPV vaccines. Previous studies [33–36] have highlighted cost concerns as a major issue impeding the uptake of HPV vaccine, this study reveals knowledge gaps about the vaccine and accessibility as the more important factors than cost of the vaccine in our environment. Currently in Nigeria, HPV vaccine is optional, not included in the national immunization schedule and also not subsidized by government. Agida et al. [11] in their study observed that regardless of the current cost of the vaccine in Nigeria, acceptance was high among parents who were aware of the vaccine. Adequate information also needs to be provided to the parents and caregivers to dispel all wrong perceptions about HPV vaccine.

### Table 5 Knowledge about the risk factor for cervical cancer

| What are the risk factors for cervical cancer? | Frequency n = 508 | Percent |
|---|---|---|
| Don’t know | 265 | 52.2 |
| Death | 98 | 19.3 |
| Sexual transmitted disease/unprotected sex | 7 | 1.4 |
| Early sex and multiple sex partners | 4 | 0.8 |
| Multiple sexual partners | 5 | 1.0 |
| Sexual promiscuity | 1 | 0.2 |
| Infection | 62 | 12.2 |
| Neck injury | 1 | 0.2 |
| Cancer of the cervix | 3 | 0.6 |
| Injury in the cervix | 20 | 3.9 |
| Pain in the cervix/womb | 17 | 3.3 |
| Affection | 1 | 0.2 |
| Family planning inserts | 2 | 0.4 |
| Vaginal Bleeding | 3 | 0.6 |
| HPV infection | 12 | 2.4 |
| Instrumentation in female private part | 2 | 0.4 |
| Sickness | 1 | 0.2 |
| Low fertility | 2 | 0.4 |
| Heredity | 1 | 0.2 |
| Damage of the uterine wall | 1 | 0.2 |

### Table 6 Reason(s) for not giving HPV vaccine by those aware of the vaccine

| REASON | Frequency n = 132 | Percent |
|---|---|---|
| I don’t know how to access the vaccine | 123 | 93.2 |
| My daughter is too young to have risk of cervical cancer | 94 | 71.2 |
| I am worried about the safety of the vaccine | 47 | 35.6 |
| I am not sure of the effectiveness of the vaccine | 26 | 19.7 |
| The decision would be made by the child herself | 108 | 81.8 |
| The vaccine is expensive | 25 | 18.9 |
Awareness campaigns in places like ante-natal clinics, parents-teachers forums of schools etc., particularly amongst caregivers of young female children is pivotal to improving uptake of HPV vaccination and reducing incidence of cervical cancer in Nigeria. Governments should subsidize and include the HPV vaccine in National immunization schedules to encourage uptake and subsequently reduce the incidence of cervical cancer.

Conclusions
Despite high levels of education, the following, awareness of HPV infections and cervical cancer, and their related risk factors and HPV vaccines were low among caregivers of female children in Enugu, south-East, Nigeria.

Similarly history of HPV vaccination among the children of the respondents was low, accessibility and affordability was the most common challenge among those aware of the vaccine. There is a need for massive and sustained awareness creation to step up HPV vaccination in Nigeria.

References
1. Aral SO, Holmes KK. The epidemiology of STIs and their social and behavioural determinants: industrialized and developing countries. Sexually Transmitted Diseases. 4th ed. New York: McGraw-Hill; 2008. p. 53–92.
2. Syrjänen S, Puranen M. Human papilloma virus infections in children: the potential role of maternal transmission. Crit Rev Oral Biol Med. 2000;11(2):259–74.
3. Prat J. Pathology of cancers of the female genital tract. Int J Gynecol Obstet. 2012;119:5137–50.
4. Stanley M. Human papilloma vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol). 2008;20:388–94.
5. Steller MA. Cervical cancer: A vaccine-preventable malignancy. Female Patient. 2006;3:9–10.
6. Erickson BK, Avarez RD, Huh WK. Human papilloma virus: what every provider should know. Am J Obstet Gynecol. 2013;208:169–75.
7. Haefner HK. Update on Human papilloma virus. Supplement to SRM. Nov 2008:15–6.
8. Paavonen J. Human papilloma virus infection and the development of cervical cancer and related genital neoplasia. Int J Infect Dis. 2007;11(Suppl 2):S3–9.
9. Escobar PF, Orit JW. The human papilloma virus vaccine: current status. Female Patient. 2008;3:18–22.
10. Patanwala IY, Bauer HM, Miyamoto J, Park IU, Huchko NJ, Smith-McCune KK. A systematic review of randomized trials assessing human papilloma virus testing in cervical screening. Am J Obstet Gynecol. 2013;208:343–53.
11. Agida TE, Akaka GO, Ishay AK, Ekele B. Knowledge and perception of human papilloma virus vaccine among the antenatal women in a Nigerian tertiary hospital. Niger Med J. 2015;56:23–7.
12. Syrjänen S. Current concepts on human papilloma virus infections in children. APAMIS. 2010;1186–7:494–509.
13. Holland WW, Stewart S. Screening in adult women, screening in health care. Nuffield Nuffield Provincial Trust; 1990. p. 155–72.
14. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.
15. Louie KS, de Sanjose S, Mayaud P. Epidemiology and prevention of human papilloma virus and cancer in sub-Saharan Africa: a comprehensive review. Tropical Med Int Health. 2009;14:1287–302.
16. Parkin DM, Stas F, Chirenje M, Stein L, Abatz R, Wabinga H. Cancer in indigenous Africans-burden, distribution and trends. Lancet Oncol. 2008;9:868–92.
17. Moroumke SG, Ayorinde JB, Benedict AO, Adebayo FO, Adeyemo FO, et al. Epidemiology and incidence of common cancers in Nigeria. J Cancer. Biol Res. 2017;5:1109.
18. Brun L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, De Sanjosé S. COI/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papilloma Virus and Related Diseases in Nigeria. Summary Report 27 July 2017. [Accessed 5th aug 2018].
19. Awolade O, Adebamoye AA, Awolade DF, Fayankinnu VB, Dolapo DC. Cancer distribution pattern in South-Western Nigeria. Tanzan J Health Res. 2011;13(2):125–31.
20. Raffindadi AH, Ahmed SA. Cancer in women and children in Zaria. Niger J. Proceedings of the association of pathologists in Nigeria Scientific Conference. 2005.
21. Ahmed SA, Sabitu K, Idris SH, Ahmed R. Knowledge, attitude and practice of cervical cancer screening among market women in Zaria, Nigeria. Niger Med J. 2013;54:316–9.
22. Pisani P, Parkin DM, Bray F, Ferley J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83:870–74.
23. Erickson BK, Avarez RD, Huh WK. Human papilloma virus: what every provider should know. Am J Obstet Gynecol. 2013;208:169–75.
24. Human papilloma virus vaccination. The American College of Obstetricians and Gynaecologists Committee Opinion no. 588. Obstet Gynecol. 2014;123:712–8.
25. Markowitz LE, Dunne EF, Saraiva M, Lawson HW, Chesson H, Unger ER. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papilloma virus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–26.
26. Dahlström LA, Tran TN, Lundholm C, Young C, Sundström K, Sparén P. Attitudes to HPV vaccination among parents of children aged 12-15 years—a population based survey in Sweden. Int J Cancer. 2010;126(2):500–7.

27. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al; GlaxoSmithKline HPV Vaccine Study Group. Efficacy of bivalent L1 virus-like particle vaccine in prevention of infection with human papilloma virus types 16 and 18 in young women: a randomized control trial. Lancet 2004; 364:1757–1765.

28. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papilloma virus (HPV)-16/18 ASO4-adjuvanted vaccine against cervical infection and pre-cancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomized study in young women. HPV PATRICIA Study Group. Lancet. 2009;374:301–14.

29. Munaz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. Impact of human papilloma virus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102:325–39.

30. Odetola TD, Ekpo K. Nigerian Women’s perceptions about human papilloma virus immunizations. J Community Med Health Educ. 2012;2:191.

31. Olowookere SA, Abiye-Kuteyi EA, Fasure HA, Fayose O, Onakpoma F, Ibitoye A. Awareness and uptake of human papilloma virus vaccination and cervical cancer screening among female undergraduate students in a tertiary institution in Nigeria. Nigerian Journal of Family Practice. 2012;3:27–32.

32. Ugwu EO, Obi SN, Ezechukwu PC, Okafor II, Ugwu AO. Acceptability of human papilloma virus vaccine and cervical cancer screening among female health-care workers in Enugu, Southeast Nigeria. Niger J Clin Pract. 2013;16:469–52.

33. Ezem BU. Awareness and uptake of cervical cancer screening in Owerri, south-eastern Nigeria. Ann Afr Med. 2007;6:94–8.

34. Ezenwa BN, Balogun MR, Okafor IP. Mothers’ human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Women’s Health. 2013;5:371–7.

35. Makwe CC, Anorlu RI. Knowledge of and attitude towards human papilloma virus infection and vaccines among female nurses at a tertiary hospital in Nigeria. Int J Womens Health. 2011;3:313–7.

36. Nnodu O, Erinosho L, Jamda M, Olanjy O, Adelaiye R, Lawson L, et al. Knowledge and attitudes towards cervical cancer and human papilloma virus: a Nigerian pilot survey. Afr J Reprod Health. 2010;14:95–108.